J&J/Merck's Mevacor OTC Switch Appears To Be "Not Approvable" At FDA
This article was originally published in The Pink Sheet Daily
Executive Summary
Merck's receipt of a letter from FDA on the eve of the Feb. 24 user fee deadline, coupled with statements from the agency, suggest that FDA deemed the statin "not approvable" for OTC sale. Advisory committees voted against the switch in January.
You may also be interested in...
Mevacor Daily OTC Switch Rejected Based On Patient Inability To Self Select
FDA joint committee finds that current system does not ensure appropriate patient self-selection for cholesterol-lowering therapy. Committee votes 20-3 against OTC marketing for Mevacor Daily. Behind-the-counter strategy for pharmacy urged.
Judge Orders FDA, Food Safety Group To Set FSMA Implementation Date
FDA’s delays in implementing the Food Safety Modernization Act violated FSMA and the Administrative Procedures Act, a federal court finds in an April 22 order. The agency must meet with plaintiff Center for Food Safety to agree on new implementation deadlines by May 20.
Judge Orders FDA, Food Safety Group To Set FSMA Implementation Date
FDA’s delays in implementing the Food Safety Modernization Act violated FSMA and the Administrative Procedures Act, a federal court finds in an April 22 order. The agency must meet with plaintiff Center for Food Safety to agree on new implementation deadlines by May 20.